A Phase 1 interventional study of GBT021601 in Renal Impairment, sponsored by Pfizer. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.
Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 34th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2023, is one of 23 in phase 1, and was the 32nd registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18–80 · Healthy volunteers
Pfizer · Sites in United States
Ages 18–90 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 1 · Phase 3 4 · Phase 4 8
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 30 across the 36 interventional studies, 59 across the 1 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Renal Insufficiency by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07315360PfizerA Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function | 2027-03-13 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Renal Insufficiency by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Renal Impairment study of GBT021601.
This is a Phase 1, two-part, non-randomized, open-label, parallel group study to evaluate the PK, safety, and tolerability of GBT021601 following a single dose administration in adult participants with RI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GBT021601
Drug: GBT021601
Oral
Concentration of GBT021601 in whole blood and plasma
To evaluate the single-dose whole blood and plasma PK of GBT021601 in participants with renal impairment (RI)
Time frame: Up to 112 Days
Single-dose PK parameters
To evaluate the single-dose whole blood and plasma PK of GBT021601 in participants with renal impairment
Time frame: Up to 112 Days
Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs
To evaluate the safety and tolerability of single dose GBT021601 in participants with renal impairment
Time frame: Up to 112 Days
Incidence of treatment-emergent adverse events (TEAEs), clinically significant changes in laboratory assessments, electrocardiograms (ECGs), and vital signs
To evaluate the safety and tolerability of GBT021601 in ESRD participants receiving IHD following a single dose
Time frame: Up to 112 Days
Single-dose PK parameters for GBT021601 in RBC
To evaluate the single-dose RBC PK of GBT021601 in participants with RI
Time frame: Up to 112 Days
Amount of GBT021601 excreted in urine
To evaluate the urinary excretion of GBT021601 in participants with RI following a single dose
Time frame: Up to 112 Days
Descriptive analysis of eGFR versus PK exposure parameters
The relationship of eGFR, as estimated using serum creatinine and serum cystatin C on GBT021601 PK exposure in participants with RI
Time frame: Up to 112 Days
Protein binding of GBT021601 in plasma
To evaluate the protein binding of GBT021601 in participants with RI
Time frame: Up to 112 Days
Single-dose PK parameters for GBT021601 in RBC
To evaluate the single-dose RBC PK of GBT021601 in participants with ESRD receiving IHD
Time frame: Up to 112 Days
Extraction ratio of GBT021601 via dialysis and concentration of GBT021601 in dialysate
To evaluate the clearance of GBT021601 by IHD in participants with ESRD
Time frame: Up to 112 Days
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jun 2023 to primary completion in Jul 2024, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osivelotor